Deslorelin vs Tesamorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profileTesamorelin
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.
Full profile| Deslorelin | Tesamorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | Egrifta, Egrifta SV, TH9507, GHRH analog |
| Evidence | Research-stage | FDA-approved |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 1.28mg–2mg mg, once daily (subcutaneous) |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Subcutaneous injection (abdomen, with site rotation) |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia |
| Cited sources | 2 references | 5 references |
Key differences
- Evidence level differs: Deslorelin is research-stage, while Tesamorelin is fda-approved.
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
- Dosing units differ: Deslorelin is dosed in mcg, Tesamorelin in mg — they operate at different scales.
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; Tesamorelin is once daily (subcutaneous).
- Research depth: this profile cites 2 sources for Deslorelin vs 5 for Tesamorelin.
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
Tesamorelin
Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.